yttrium radioisotopes has been researched along with Mesothelioma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Higashi, T; Kaneko, MK; Kato, Y; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB | 1 |
| Baidoo, KE; Brechbiel, MW; Garmestani, K; Milenic, DE; Nayak, TK | 1 |
| Gans, S; Kramer, G; Leer, J; Rijnders, A | 1 |
3 other study(ies) available for yttrium radioisotopes and Mesothelioma
| Article | Year |
|---|---|
Therapeutic efficacy evaluation of radioimmunotherapy with
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Membrane Glycoproteins; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; Radioimmunotherapy; Rats; Treatment Outcome; Up-Regulation; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2019 |
HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody Specificity; Cetuximab; ErbB Receptors; Flow Cytometry; Humans; Isothiocyanates; Mesothelioma; Mice; Molecular Targeted Therapy; Panitumumab; Pentetic Acid; Positron-Emission Tomography; Time Factors; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2011 |
Long term survival of a patient with malignant pleural mesothelioma as a late complication of radiotherapy for Hodgkin's disease treated with 90yttrium-silicate.
Topics: Hodgkin Disease; Humans; Male; Mesothelioma; Middle Aged; Neoplasms, Radiation-Induced; Pleural Neoplasms; Survivors; Yttrium Radioisotopes | 2000 |